Will Clodfelter, MBA - Chief Executive Officer
Will has over 15 years leadership experience working in biopharmaceutical and medical device roles ranging from startups to Fortune 50 organizations. Prior to joining Medicus in 2016, he was the founder and Managing Director of Ponto Ventures LLC, a medical device consultancy based in San Diego, California. From 2007 to 2013 he was the Director of Device Commercialization at Amylin Pharmaceuticals, now a subsidiary of Astra Zeneca. In addition to his device development roles, he also was head of New Product Planning and was a member of the Decision Sciences group at Amylin. He has previously held Corporate Strategy and Business Development roles at Eli Lilly and has been an entrepreneur with both product-based and consultancy startups. Will has a BS in Structural Engineering from Purdue University and an MBA in Entrepreneurship and Marketing from the Indiana University Kelley School of Business.
Linda Black, DVM, PhD - COO, VP of Clinical Development
Dr. Black has broad experience in human and animal health, with extensive experience in development and commercialization of stem cell therapies for pets as the former VP of Product Development for Vet-Stem Biopharma and CEO of SciStem Therapeutics. Prior to those roles, she consulted exclusively for Merial, Ltd supporting aspects of R&D, marketing, and sales divisions. Dr. Black is responsible for Medicus Biosciences operations, manufacturing and R&D, and leads business development, clinical and product development for Medicus Veterinary Biosciences. Dr. Black holds a DVM from University of Wisconsin-Madison, a PhD in Cell and Molecular Biology from University of Pennsylvania and completed her post doctoral fellowship at SmithKline Beecham (GlaxoSmithKline).
Clayton Coder, Director of Sales and Marketing
Clayton Coder Joined Medicus Biosciences as Director of Sales and Marketing in 2016. Mr. Coder brings over 25 years of experience in pharmaceutical and veterinarian sales and marketing. He has hands-on experience with direct customers as well as leadership experience in all critical aspects of commercialization while working at Merck Animal Health and at Eli Lilly and Company. During his tenure at Merck he successfully led the development and implementation of contracts with key distributors, managed distribution outlets, and served as the lead for sales and sales training within distribution. Mr. Coder was also tasked with development of annual business plans while managing accounts that generated over $200 million in revenue on an annual basis. He earned a B.S. in Business Administration with emphasis on Marketing Management from Upper Iowa University.
April Treadwell, MBA, Finance
April brings over 15 years of experience in accounting and financial management in biotechnology companies focused on human and animal health. She has worked in start-up and early phase environments where she has expertise in forecasting, financial analysis, implementing accounting systems and streamlining operations, as well as working with established companies to redesign procedures. She has handled compliance with international licensing agreements and maintained financial records for government contracts. April earned her undergraduate degree in Equine Science from California State Polytechnic University and a Master’s in Business Administration from Webster University.
Don Rindell, MBA, Business Development
Don Rindell has more than 25 years of senior executive experience in the life sciences industry. He has held executive roles in global corporate development, business development and device/technology strategy for several US and European pharmaceutical and medical device companies. Don most recently served as Senior Director of Corporate Development at Amylin Pharmaceuticals, and has led a number of key global transactions with partners including Lilly, Shionogi Pharmaceuticals, BIOCON, and Takeda Pharmaceuticals. Don is a member of the Board of Directors of publicly traded TearLab (NASDAQ: TEAR), and advisor to two other medical device companies. He has previously held senior executivepositions at MDG, CardioNet, Advanced Tissues Sciences, Braun/Thermoscan, and Hybritech. Don received his B.A. degree in Economics from the College of Wooster and an M.B.A. from Pepperdine University Graduate School of Business.
Joachim Osther - Marketing Lead
Joachim Osther brings over 16 years of pharmaceutical and biotech sales and commercialization experience. His background in sales and marketing includes leadership positions in Pharmaceutical Sales, In-Line Marketing and Product Launches for Eli Lilly and Company, Amylin Pharmaceuticals and recently as the founder and owner of a healthcare consultancy. He is also a published author on human factor design in medical devices and has been interviewed by Medical Marketing and Media as a subject matter expert. Mr. Osther is a member of the Board of Directors for Dana Genetic A/S, an oncology research and development company. Mr. Osther earned a B.A. in Exercise Physiology and an A.S. as a Physical Therapist Assistant from Washburn University.